Comparative Pharmacology
Head-to-head clinical analysis: INTRAROSA versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTRAROSA versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
INTRAROSA vs LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intrarosa (prasterone) is an exogenous dehydroepiandrosterone (DHEA) that is converted locally to androgens and estrogens, primarily testosterone and estradiol, in vaginal cells. It restores the hormonal environment of the vaginal tissue, improving epithelial integrity and reducing symptoms of vulvovaginal atrophy.
Combination hormonal contraceptive. Ethinyl estradiol and levonorgestrel inhibit gonadotropin release (FSH, LH), suppressing ovulation. Progestin effect: thickens cervical mucus, alters endometrial receptivity. Ferrous fumarate provides iron supplementation during placebo phase.
6.5 mg administered intravaginally once daily at bedtime for 21 days.
One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol, 75 mg ferrous fumarate) orally once daily at the same time for 21 consecutive days, followed by one ferrous fumarate-only tablet (75 mg) orally once daily for 7 days (28-day cycle).
None Documented
None Documented
Terminal elimination half-life is approximately 3.5 hours, allowing for twice-daily dosing in maintenance therapy.
Levonorgestrel: ~25 hours, steady-state after 5 days. Ethinyl estradiol: ~13 hours (7–20). Ferrous fumarate: not applicable.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose; biliary/fecal elimination accounts for the remaining 40%, with minimal hepatic metabolism.
Levonorgestrel: ~45% renal, ~32% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Ferrous fumarate: iron excreted in feces as unabsorbed; minimal renal.
Category C
Category D/X
Estrogen
Estrogen